Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(−2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Valle, J W, Dangoor, A, Beech, J, Sherlock, D J, Lee, S M, Scarffe, J H, Swindell, R, Ranson, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361887/
https://www.ncbi.nlm.nih.gov/pubmed/15700038
http://dx.doi.org/10.1038/sj.bjc.6602394
_version_ 1782153324998426624
author Valle, J W
Dangoor, A
Beech, J
Sherlock, D J
Lee, S M
Scarffe, J H
Swindell, R
Ranson, M
author_facet Valle, J W
Dangoor, A
Beech, J
Sherlock, D J
Lee, S M
Scarffe, J H
Swindell, R
Ranson, M
author_sort Valle, J W
collection PubMed
description Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(−2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
format Text
id pubmed-2361887
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23618872009-09-10 Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study Valle, J W Dangoor, A Beech, J Sherlock, D J Lee, S M Scarffe, J H Swindell, R Ranson, M Br J Cancer Clinical Study Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(−2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months. Nature Publishing Group 2005-02-28 2005-02-08 /pmc/articles/PMC2361887/ /pubmed/15700038 http://dx.doi.org/10.1038/sj.bjc.6602394 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Valle, J W
Dangoor, A
Beech, J
Sherlock, D J
Lee, S M
Scarffe, J H
Swindell, R
Ranson, M
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
title Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
title_full Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
title_fullStr Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
title_full_unstemmed Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
title_short Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
title_sort treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (pld): results of a phase ii study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361887/
https://www.ncbi.nlm.nih.gov/pubmed/15700038
http://dx.doi.org/10.1038/sj.bjc.6602394
work_keys_str_mv AT vallejw treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy
AT dangoora treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy
AT beechj treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy
AT sherlockdj treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy
AT leesm treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy
AT scarffejh treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy
AT swindellr treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy
AT ransonm treatmentofinoperablehepatocellularcarcinomawithpegylatedliposomaldoxorubicinpldresultsofaphaseiistudy

Ejemplares similares